Search results
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 12 hours agoFollicular lymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma...
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
MedPage Today· 6 days agoOnly one of 724 patients treated with chimeric antigen receptor (CAR) T-cell therapy for B-cell ...
AstraZeneca reports positive data from Phase III mantle cell lymphoma trial
Clinical Trials Arena via Yahoo Finance· 17 hours agoAstraZeneca Oncology R&D executive vice-president Susan Galbraith said: “The ECHO trial data...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 14 hours agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 7 hours agoThe trial tested the drug in combination with chemoimmunotherapy, bendamustine and Roche/Biogen’s...
Reliable Subaru and The Leukemia & Lymphoma Society donate blankets to cancer patients
Springfield News-Leader via Yahoo News· 3 days agoReliable Subaru partnered with The Leukemia & Lymphoma Society to support patients facing cancer at...
Three-Drug Regimen Shows OS Benefit in Third-Line DLBCL
MedPage Today· 23 hours agoLoretta Nastoupil, MD, leads a discussion on the ECHELON-3 trial results
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 12 hours agoThis trial evaluated the efficacy of AbbVie/Roche's Venclexta (venetoclax) and BeiGene's Brukinsa...
Kymera shares hold Buy rating on PoC data By Investing.com
Investing.com· 14 hours agoKT-333's mechanism of action was further supported by biomarker data regarding STAT3, phosphorylated...
...Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory...
Morningstar· 3 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma – The study met ...